Meda Pharma S.p.A.

Meda Pharma S.p.A. specializes in topical dermatological treatments, primarily designed for skin and mucosal applications. Their portfolio includes cryotherapy-based solutions for skin lesions like warts (e.g., *EndWarts Original*), lotions and shampoos for skin conditions (e.g., *Licinic Lotion*, *Licinic ULTRA Shampoo*), nasal irrigation devices (e.g., *Kamillosan Ocean Nasendusche*), and topical emollients (e.g., *Prioderm Dimeticon Lotion*). These devices are intended for localized treatment of dermatological or mucosal issues.

Meda Pharma S.p.A. is based in Italy, which means its devices are developed and marketed in compliance with the European Union’s Medical Device Regulations (MDR). Since the company operates within the EU, its products are registered in the eudamed database—a central EU repository for medical device information—and must meet MDR requirements for classification, labeling, and post-market surveillance.

Meda Pharma S.p.A.’s devices fall into three classification categories under EU regulations: Class I (low-risk devices like some topical lotions), Class IIa (moderate-risk devices such as certain dermatological treatments), and Class IIb (higher-risk devices, including some cryotherapy-based solutions for skin lesions). Classification depends on factors like intended use, duration of application, and potential risks to patient safety, as defined by EU MDR guidelines.

Yes, all of Meda Pharma S.p.A.’s medical devices are registered in the eudamed database, which is the official EU repository for medical device information. This registry ensures transparency and compliance with EU Medical Device Regulation (MDR) requirements, allowing healthcare professionals, regulators, and patients to access details about the devices’ classification, manufacturer, and regulatory status.

Certain devices, such as cryotherapy-based solutions for skin lesions (e.g., *EndWarts Original*), are classified as Class IIb due to their potential to cause significant harm if misused or improperly applied. EU MDR categorizes devices based on risk factors like the duration of contact with the body, the likelihood of adverse effects, and the need for post-market surveillance. Higher-risk devices require stricter regulatory oversight to ensure safety and efficacy.